Coherus Chief: FTC Must Probe Originators’ Anti-Competitive Tactics

 
• By Aidan Fry

Bundled rebate contracts for biologic brands that are designed to thwart biosimilar competition in the US are anti-competitive practices that deserve Federal Trade Commission action, biosimilar developer Coherus’ chief argues in a newspaper opinion piece.

FTC
The Federal Trade Commission must act on anti-competitive biologics rebate bundling that is stifling biosimilars uptake, Coherus chief Denny Lanfear insists • Source: Shutterstock

More from Biosimilars

More from Products